


Article

Multicomponent Synthesis of New Fluorescent Boron Complexes Derived from 3-Hydroxy-1-phenyl-1*H*-pyrazole-4-carbaldehyde

Viktorija Savickienė¹, Aurimas Bieliauskas² , Sergey Belyakov³ , Eglė Arbačiauskienė^{1,*} 
and Algirdas Šačkus^{2,*}

¹ Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų pl. 19, LT-50254 Kaunas, Lithuania; viktorija.dargyte@ktu.lt

² Institute of Synthetic Chemistry, Kaunas University of Technology, K. Baršausko g. 59, LT-51423 Kaunas, Lithuania; aurimas.bieliauskas@ktu.lt

³ Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia; serg@osi.lv

* Correspondence: egle.arbaciauskiene@ktu.lt (E.A.); algirdas.sackus@ktu.lt (A.Š.)

Abstract: Novel fluorescent pyrazole-containing boron (III) complexes were synthesized employing a one-pot three-component reaction of 3-hydroxy-1-phenyl-1*H*-pyrazole-4-carbaldehyde, 2-aminobenzenecarboxylic acids, and boronic acids. The structures of the novel heterocyclic compounds were confirmed using ¹H-, ¹³C-, ¹⁵N-, ¹⁹F-, and ¹¹B-NMR, IR spectroscopy, HRMS, and single-crystal X-ray diffraction data. The photophysical properties of the obtained iminoboronates were investigated using spectroscopic techniques, such as UV–vis and fluorescence spectroscopies. Compounds display main UV–vis absorption maxima in the blue region, and fluorescence emission maxima are observed in the green region of the visible spectrum. It was revealed that compounds exhibit fluorescence quantum yield up to 4.3% in different solvents and demonstrate an aggregation-induced emission enhancement effect in mixed THF–water solutions.

Keywords: pyrazoles; iminoboronates; fluorescence; aggregation-induced emission enhancement



Citation: Savickienė, V.; Bieliauskas, A.; Belyakov, S.; Arbačiauskienė, E.; Šačkus, A. Multicomponent Synthesis of New Fluorescent Boron Complexes Derived from 3-Hydroxy-1-phenyl-1*H*-pyrazole-4-carbaldehyde. *Molecules* **2024**, *29*, 3432. <https://doi.org/10.3390/molecules29143432>

Academic Editor: Agostina-Lina Capodilupo

Received: 28 June 2024

Revised: 18 July 2024

Accepted: 19 July 2024

Published: 22 July 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Heterocyclic systems possessing a pyrazole ring have found diverse applications in various fields, including pharmaceuticals [1,2], agrochemicals [3,4], and functional materials [5,6]. Among other heterocycles, pyrazole-ring-containing compounds often exhibit anticancer [7,8], anti-inflammatory [9], and antidiabetic activities [10]. Moreover, it is a common structural motif in a variety of drug substances. Anti-inflammatory celecoxib [11], antipsychotic 3-cyano-*N*-(1,3-diphenyl-1*H*-pyrazol-5-yl)benzamide (CDPPB) [12], antiobesity rimonabant [13], and analgesic difenamizole [14] can be highlighted as notable examples. Investigations toward agrochemical compounds have also led to the discovery of pyrazole-containing fungicides [15], insecticides [16], and herbicides [17]. In material sciences, pyrazole compounds have emerged as chemosensors [18], biological imaging agents [19], and metal–organic frameworks (MOFs) [20].

Over the years, many methods have been used to synthesize pyrazole derivatives, including ring formation via the cyclocondensation of hydrazines, with carbonyl systems and dipolar cycloadditions being the most relevant [21,22]. Another approach to synthesizing pyrazole derivatives is related to the functionalization of pyrazole ring, and a number of reported synthetic late-stage pyrazole functionalizations rely on (pseudo)halogenation and following transition-metal catalysis or direct C–H functionalization [23,24]. A multicomponent reaction (MCR) approach has also been successfully applied to synthesize pyrazole-containing heterocyclic systems [25,26]. Multicomponent reactions can be highlighted as one of the most valuable tools used by researchers to synthesize heterocyclic compounds, as they meet the principles of sustainable chemistry, are cost- and time-effective, and are atom- and bond-economic [27,28]. Recent examples of multicomponent

reactions for synthesizing pyrazole-containing compounds include the synthesis of biheterocyclic pyrazole-linked thiazole or imidazole derivatives from appropriate aryl glyoxal, aryl thioamide, and pyrazolones [29] or the formation of stable pyrazole amides via a Ugi four-component reaction [30]. A multicomponent synthesis approach was applied to obtain multisubstituted pyrazole derivatives from alkynes, nitriles, and titanium imido complexes [31]. We have also reported the synthesis and structural elucidation of several series of novel biheterocyclic pyrazole-containing compounds by employing different types of multicomponent reactions, starting from 3-alkoxy-1*H*-pyrazole-4-carbaldehydes [32].

The boron (III)-containing complexes, especially the tetracoordinated species, have emerged as organic fluorophores. The boron-dipyrrromethene (BODIPY) family of dyes have proved their superior characteristics as they exhibit excellent optical properties, are compatible with a wide range of reaction conditions, easy to functionalize, stable as solids and solutions [33–36]. The wide application of BODIPY dyes includes cell imaging [37,38], photodynamic therapy [39–41], metal ion detection [42,43]. As one of the alternatives for the BODIPYs, also the condensed complexes of boronic acids and salicylidenehydrazones (BASHYs) have been reported [44–51]. Compounds display low luminescence in organic solvents but demonstrate a remarkable aggregation-induced emission enhancement (AIEE) effect. BASHYs have been widely investigated and proven to be interesting as highly fluorescent dyes [44,46,51] or multivalent cancer-cell-targeting drug conjugates [47,48]. However, the synthesis and investigation of boron complexes using heterocyclic carbaldehydes with carbaldehyde moiety adjacent to the hydroxy group instead of salicylic counterparts is still limited.


In continuation of our interest in synthesizing and investigating the properties of various pyrazole derivatives [52–57], herein, we report an efficient one-pot multicomponent synthesis of novel pyrazole ring-containing iminoboronates, starting from 3-hydroxy-1-phenyl-1*H*-pyrazole-4-carbaldehyde, and investigate the photophysical properties of the obtained boronic compounds.

2. Results and Discussion

2.1. Chemistry

The synthesis of iminoboronates is usually achieved via a one-pot, three-component reaction of salicylaldehydes and anthranilic acids condensing to corresponding imines and double condensation with boronic acids. The reaction requires no catalyst, and usually, target products are formed while refluxing the reaction mixture in methanol [45], ethanol [46], acetonitrile [44,47,48], carbon tetrachloride [49], or water [50] media.

The synthesis of the pyrazole-containing organoboron compounds **4a–k** was accomplished by starting from 3-hydroxy-1-phenyl-1*H*-pyrazole-4-carbaldehyde (**1**) [58], 2-aminobenzenecarboxylic acids (**2a–c**), and boronic acids (**3a–d**), and employing an MCR approach (Scheme 1). Refluxing the reaction mixture in ethanol for 48 h, cooling, filtrating, and washing the formed solid provided the target products **4a–k**. Efforts to obtain a higher yields by stirring the reaction mixture under MW irradiation [45] or switching the reaction solvent to methanol [47], acetonitrile [44,47,48], or carbon tetrachloride [49] did not improve the results. The scope of the reaction was evaluated using 2-aminobenzenecarboxylic acids substituted with 5-chloro or 5-methyl moieties as well as a variety of boronic acids containing both electron-donating (methyl, methoxy) and electron-withdrawing (fluoro, trifluoromethyl) substituents. The substituents of the reacting materials did not influence the result of the reaction outcome, and the products were formed in a 47–72% yield. All the compounds were obtained as yellow solids stable at ambient conditions. Attempts to obtain an analogous boron complex by employing 4-(diethylamino)phenylboronic acid were unsuccessful, as only unreacted starting materials could be observed in the reaction mixture. The complexes bore a chiral boron center and were obtained as a racemic mixture [45].



Scheme 1. Synthesis of compounds **4a–k**. Reagents and conditions: EtOH, 70 °C, 48 h.

2.2. NMR Spectroscopic Investigations

The structure of compounds **4a–k** was unambiguously assigned based on the HRMS, IR, and NMR spectral data analysis. We have carried out detailed NMR studies for the obtained novel compounds to fully map ^1H , ^{13}C , ^{15}N , ^{19}F , and ^{11}B signals. A detailed analysis of the representative compound **4a** is given in Figure 1a–c. The formation of the N \rightarrow B coordination bond was evidenced via NMR spectroscopy. The ^{11}B NMR spectrum of **4a** displays one broad resonance signal at δ 6.1 ppm, which agrees with the data of other tetracoordinated boron-atom-bearing Schiff bases [44,47]. In addition, the remaining key information for structure elucidation was obtained using two-dimensional NMR spectroscopy techniques such as ^1H - ^1H ROESY, ^1H - ^{13}C HMBC, ^1H - ^{13}C H2BC, ^1H - ^{15}N HMBC, and 1,1-ADEQUATE (Figure 1c). For instance, the most downfield methine proton in the ^1H NMR spectrum (singlet, δ 9.65 ppm) was assigned to the new ($-\text{CH}=\text{N}^+$) bond from the iminoboronate moiety, while another distinct methine signal (singlet, δ 9.24 ppm) was assigned to the pyrazole 5-H proton from the 1*H*-pyrazol-4-yl moiety.




Figure 1. (a) ^1H NMR (italics) and ^{15}N NMR (bold) chemical shifts [ppm, ref. TMS (^1H) and CH_3NO_2 (^{15}N)] of compound **4a** in $\text{DMSO}-d_6$; (b) ^{13}C NMR (regular) and ^{11}B NMR (underlined) chemical shifts [ppm, ref. TMS] of compound **4a** in $\text{DMSO}-d_6$; (c) relevant 1,1-ADEQUATE, ^1H - ^{13}C HMBC, ^1H - ^{15}N HMBC, ^1H - ^{13}C H2BC, and ROE correlations.

An unambiguous assignment of the aforementioned methine protons was easily achieved from the long-range HMBC correlation data. The pyrazole 5-H proton solely showed ^1H - ^{15}N HMBC correlations with the neighboring N-1 “pyrrole-like” (δ -168.9 ppm) and N-2 “pyridine-like” (δ -117.9 ppm) nitrogen atoms. While the methine proton from the iminoboronate moiety correlated with the neighboring nitrogen atom (δ -194.3 ppm) only. These findings were further supported by the distinct long-range ^1H - ^{15}N HMBC and ^1H - ^{13}C HMBC correlations between the methine protons (phenyl 2’(*6*’)-H and 3’’’-H) from the neighboring aryl moieties and the corresponding carbon or nitrogen atoms.

The ^1H - ^1H ROESY spectrum of **4a** further elucidated the connectivities based on through-space correlations. For example, distinct ROEs were observed between the pyrazole ring proton 5-H, the phenyl group 2’(*6*’)-H protons (δ 7.92–7.95 ppm), and the most downfield methine proton from the iminoboronate moiety. The aforementioned methine proton also correlated with the 3’’’-H proton (δ 8.12 ppm), confirming their proximity in space. Having successfully identified all the main ^1H spin systems, the remaining protonated and quaternary carbons were easily assigned from the ^1H - ^{13}C H2BC and 1,1-ADEQUATE spectral data.

The newly formed iminoborates **4a–k**, which contain a pyrazole ring, consist of three nitrogen atoms. The chemical shifts of the N-1 “pyrrole-like” and N-2 “pyridine-like” nitrogen atoms from the 1*H*-pyrazol-4-yl moiety were in the ranges from δ -168.0 to -169.3 ppm and from δ -117.3 to -117.9 ppm, respectively. The nitrogen atom in compounds **4a–d,f–h**, from the iminoboronate moiety ($-\text{CH}=\text{N}^+$), resonated from δ -192.9 to -194.3 ppm, while in the case of compounds **4e,i–k**, which contained 4''-CF₃ or 5'''-Cl groups, it resonated slightly upfield in the range from δ -196.8 to -197.9 ppm. The ¹¹B NMR spectra of **4a–k** exhibited a single broad resonance signal in the range of δ 5.6 to 6.5 ppm. Data analysis showed that the chemical shift values were highly consistent within compounds **4a–k**, thus validating the shifts for each position.

2.3. Single-Crystal X-ray Diffraction Analysis

Suitable crystals of **4a** for X-ray diffraction analysis were obtained from tetrahydrofuran. The asymmetric unit of **4a** contains two independent molecules, **A** and **B** (Figure 2), that are connected to each other via a pseudoinversion center, the coordinates of which, although close to the crystallographic point ($\frac{3}{4}, \frac{1}{4}, \frac{1}{4}$), are still different from it (the real coordinates are 0.7250, 0.2508, and 0.2698). Therefore, it is not possible to increase the symmetry of the crystal structure. Thus, this structure belongs to the triclinic crystal system. The configuration of the asymmetric boron atoms in molecules **A** and **B** are *S*- and *R*-, respectively. Thus, the substance represents a true racemate.




Figure 2. ORTEP diagram of structure **4a** with bond lengths characterizing the tetrahedron of boron (molecules **A** and **B** are connected to each other via a pseudoinversion center).

The heterocyclic system is almost planar; only one boron atom deviates from the plane of the remaining atoms of this system (the deviations are 0.573(7) Å for **A** and 0.588(7) Å for **B**). The plane of the phenyl substituent in position 10 makes a dihedral angle with the plane of the heterocycle equal to 17.3(4)° (in **A**) and 16.1(4)° (in **B**). The phenyl ring in position 7 is perpendicular to the heterocycle; the dihedral angles are 89.7(4)° in **A** and 88.8(4)° in **B**.

There is only a slight π – π interaction between molecules **A** and **B**, with the shortest atom–atom contact being 3.330(6) Å (between N10 and C13). At the same time, molecule **A** forms a strong π – π stacking interaction with the neighboring molecule **A** in the crystal structure. The distance between the least-squares planes of the heterocyclic systems equals 3.159(6) Å. In turn, the **B** molecule in the crystal of the compound also binds to the neighboring **B** molecule through the π – π stacking interaction; in this case, the distance between the least-squares planes of the heterocyclic systems equals 3.278(6) Å. Figure 3 illustrates molecular packing in the unit cell.




Figure 3. Molecular packing in crystal structure **4a**. Both molecules **A** (as well as molecules **B**) are connected by a crystallographic center of inversion; molecules **B** and **A** are connected by a pseudoinversion center.

2.4. Optical Investigations

The UV–vis absorption spectra of compounds **4a–k** were first recorded in THF (Figure 4a, Table 1, entries 1–11). The compounds possess the main absorption band in the visible region, at 397–404 nm, and two less intense bands are present in the ultraviolet range, at 309–315 and 258–262 nm. The substituents attached at various positions of the organoboron compounds **4a–k** have a negligible effect on the position of the absorption bands.




Figure 4. (a) UV–vis absorption spectra of compounds **4a–k** in different solvents: ^a THF, ^b MeOH, ^c ACN, and ^d DMF; (b) fluorescence emission spectra ($\lambda_{\text{ex}} = 400$ nm) of compounds **4a–h** in different solvents: ^a THF, ^b MeOH, ^c ACN, and ^d DMF.

Table 1. Absorption (λ_{abs} of absorption maxima and ϵ), fluorescence emission (λ_{em}), and quantum yield (Φ_f) parameters and Stokes shifts for **4a–k** in different solvents: ^a THF, ^b MeOH, ^c ACN, and ^d DMF ($\lambda_{\text{ex}} = 400$ nm) and mixed THF–water solutions ($\lambda_{\text{ex}} = 440$ nm).

Entry	Comp.	λ_{abs} (nm)	$\epsilon \times 10^3$ (dm ³ mol ⁻¹ cm ⁻¹)	λ_{em} (nm)	Stokes Shifts (nm)	Φ_f (%)	λ_{em} (nm) in H ₂ O/THF (v/v %)	Φ_f (%) in H ₂ O/THF (v/v %)
1	4a ^a	260	14.68	533	133	2.7	524 H ₂ O/THF (80/20)	26.2 H ₂ O/THF (80/20)
		310	10.61					
		400	17.80					
2	4b ^a	260	26.07	531	132	2.8	526 H ₂ O/THF (70/30)	18.8 H ₂ O/THF (70/30)
		311	30.14					
		399	30.72					
3	4c ^a	260	12.02	533	135	0.2	529 H ₂ O/THF (90/10)	11.9 H ₂ O/THF (90/10)
		309	7.69					
		398	13.17					
4	4d ^a	259	18.56	534	137	1.9	544 H ₂ O/THF (80/20)	25.4 H ₂ O/THF (80/20)
		312	13.12					
		397	22.54					
5	4e ^a	260	20.58	532	135	1.9	525 H ₂ O/THF (80/20)	30.6 H ₂ O/THF (80/20)
		312	13.68					
		397	24.65					
6	4f ^a	261	11.67	529	128	0.4	527 H ₂ O/THF (80/20)	15.1 H ₂ O/THF (80/20)
		312	7.45					
		401	14.71					
7	4g ^a	260	6.67	543	142	2.0	546 H ₂ O/THF (80/20)	52.2 H ₂ O/THF (80/20)
		313	4.52					
		401	8.11					
8	4h ^a	262	13.01	531	131	0.5	538 H ₂ O/THF (80/20)	29.2 H ₂ O/THF (80/20)
		313	7.80					
		400	15.00					
9	4i ^a	258	6.10	538	134	3.7	537 H ₂ O/THF (80/20)	7.0 H ₂ O/THF (80/20)
		315	4.60					
		404	7.88					
10	4j ^a	257	11.53	539	135	4.3	536 H ₂ O/THF (80/20)	24.4 H ₂ O/THF (80/20)
		315	8.82					
		404	14.43					
11	4k ^a	259	20.80	538	135	0.1	539 H ₂ O/THF (80/20)	19.8 H ₂ O/THF (80/20)
		315	15.48					
		403	26.77					
12	4a ^b	255	13.46	531	141	1.6	-	-
		305	7.86					
		390	14.10					
13	4a ^c	257	20.00	531	140	3.1	-	-
		306	14.03					
		391	25.17					
14	4a ^d	258	26.45	531	138	1.5	-	-
		305	17.53					
		393	28.78					

The fluorescence emissions of compounds **4a–k** were first recorded in THF (Figure 4b, Table 1, entries 1–11). The emission maxima are observed at 531–543 nm, and the Stokes shifts are in a range of 128–142 nm. Again, different substituents in the molecular structure of compounds **4a–k** do not influence the positions of emission maxima. 4'',5'''-Dimethyl-substituted compound **4g**, and 5'''-chloro-substituted analogues **4i–k**, however, show slightly bathochromic shifts compared to the other compounds. The dyes display a low quantum yield, ranging from 0.1 to 4.3%, which is in accordance with previously reported observations of similar boron complexes [44]. As iminoboronates are known to possess an AIEE effect [45], we further recorded the emission spectra of compounds **4a–k** in mixed THF–water solutions with different water contents (0–90%). As shown in Figure 5a–c, the emission intensity and quantum yield (2.7%) of compound **4a** are lower in the pure THF solution. As the water fraction increases to 80%, the emission intensity increases, and the quantum yield reaches the maximum value of 26.2%, which is about 10-fold that in the pure THF solution. Further increases in the water fraction has a negative effect on the quantum yield. This observation is in agreement with the AIEE phenomenon: when water is added, the compound precipitates, forming regular particles, which leads to enhanced

fluorescence intensity and amorphous particles, thus leading to decreased fluorescence intensity [59]. Compounds **4b–k** displayed similar behavior (Figures S1–S10).




Figure 5. (a) Fluorescence emission spectra ($\lambda_{\text{ex}} = 440$ nm) of compound **4a** in mixed THF–water solutions with different water fractions (0–90%); (b) the relationship between the quantum yield of **4a** and the water fraction in mixed THF–water solutions; (c) fluorescence photograph of compound **4a** in THF (left) and mixed THF–water (20/80) solution (right) under 365 nm wavelength UV light.

The optical properties of compound **4a** were further investigated in additional solvents, such as polar protic (MeOH) and polar aprotic (ACN and DMF). As can be observed from UV–vis spectroscopy data, the absorption bands of compound **4a** are slightly blue-shifted in more polar solvents (MeOH, ACN, DMF) in comparison to THF (Table 1, entries 12–14, Figure 4a). Fluorescence emissions of compound **4a** in MeOH, ACN and DMF possess maxima at 531 nm, and the Stokes shifts are 140, 141, and 138 nm, respectively, which are slightly larger comparing to one in THF solution (133 nm) (Table 1, entry 1, Figure 4b). Compound **4a** displays low quantum yields of 3.1, 1.6, and 1.5 in MeOH, ACN, and DMF, respectively (Table 1, entries 12–14).

3. Materials and Methods

3.1. General

All the starting materials were purchased from commercial suppliers and used as received. Flash column chromatography was performed on silica gel (60 Å; 230–400 μm ; supplied by Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The reaction progress was monitored by TLC analysis on Macherey-Nagel™ ALUGRAM® Xtra SIL G/UV254 plates (Macherey-Nagel GmbH & Co. KG, Düren, Germany) which were visualized by UV light (254 and 365 nm wavelengths).

Melting points were determined on a Büchi M-565 melting point apparatus and were not corrected. IR spectra of neat samples were recorded on a Bruker Vertex 70v FT-IR spectrometer (Bruker Optik GmbH, Ettlingen, Germany), and the results were reported as the frequency of absorption (cm^{-1}). Mass spectra were obtained using a Shimadzu LCMS-2020 (ESI⁺) spectrometer (Shimadzu Corporation, Kyoto, Japan). High-resolution mass spectra were measured on a Bruker MicroTOF-Q III (ESI⁺) apparatus (Bruker Daltonik GmbH, Bremen, Germany).

¹H, ¹³C and ¹⁵N NMR spectra were recorded in DMSO-*d*₆ solutions at 25 °C on a Bruker Avance III 700 (700 MHz for ¹H, 176 MHz for ¹³C, and 71 MHz for ¹⁵N) spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) equipped with a 5-mm TCI ¹H-¹³C/¹⁵N/D z-gradient cryoprobe. The chemical shifts (δ), were expressed relative to tetramethylsilane (TMS) in ppm. The ¹⁵N NMR spectra were referenced to neat, external nitromethane (using a coaxial capillary). ¹⁹F NMR spectra (376 MHz) and ¹¹B NMR spectra (128 MHz)

were obtained on a Bruker Avance III 400 instrument (Bruker BioSpin AG, Faellanden, Switzerland); with an absolute referencing via Ξ ratio was used. The ^1H , ^{13}C and ^{15}N NMR resonances were completely and unambiguously assigned using a combination of standard NMR spectroscopic techniques [60], including DEPT, COSY, TOCSY, ROESY, NOESY, gs-HSQC, gs-HMBC, H2BC, LR-HSQMBC and 1,1-ADEQUATE [61].

Single crystals were investigated at 160 K on a Rigaku, XtaLAB Synergy, Dualflex, HyPix diffractometer (Rigaku Corporation, Tokyo, Japan) using monochromated $\text{Cu-K}\alpha$ radiation ($\lambda = 1.54184 \text{ \AA}$). The crystal structure of **4a** was solved by direct methods [62] and refined by full-matrix least squares [63]. All nonhydrogen atoms were refined in anisotropic approximation. Hydrogen atoms were refined by riding model with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$. Crystal data for **4a**: triclinic: $a = 8.0614(2)$, $b = 14.5439(5)$, $c = 16.3846(7) \text{ \AA}$, $\alpha = 87.613(3)^\circ$, $\beta = 77.887(3)^\circ$, $\gamma = 80.845(3)^\circ$; $V = 1854.2(1) \text{ \AA}^3$, $Z = 4$, $\mu = 0.766 \text{ mm}^{-1}$, $D_{\text{calc}} = 1.408 \text{ g}\cdot\text{cm}^{-3}$; space group is $P\bar{1}$. For further details, see crystallographic data for **4a** deposited at the Cambridge Crystallographic Data Centre as Supplementary Publications Number CCDC 2313164. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK.

The UV-vis spectra were recorded on a Shimadzu 2600 UV/vis (Shimadzu Corporation, Japan). The fluorescence spectra were recorded on an FL920 fluorescence spectrometer from Edinburgh Instruments (Edinburgh Analytical Instruments Limited, Edinburgh, UK). The PL quantum yields were measured from dilute solutions by an absolute method using the Edinburgh Instruments integrating sphere excited with a Xe lamp. It was ensured that the optical densities of the sample solutions were below 0.1 to avoid reabsorption effects. All the optical measurements were performed at room temperature under ambient conditions.

The following abbreviation is used in reporting the NMR data: Pz, pyrazole. The ^1H , ^{13}C , and ^{11}B NMR spectra, as well as the HRMS data of the new compounds, are provided in Figures S11–S56 of the Supplementary Materials.

3.2. Synthetic Procedures

General procedure for the compound **4a–k** synthesis:

To a mixture of 3-hydroxy-1-phenyl-1*H*-pyrazole-4-carbaldehyde (**1**) (188 mg, 1 mmol) in EtOH (5 mL), appropriate anthranilic acid **2** (1 mmol) and phenylboronic acid **3** (1 mmol) were added. The reaction mixture was stirred at 70 °C for 48 h. After completing the reaction, as determined via TLC, the reaction mixture was cooled to room temperature. Then, the reaction mixture was filtered, and the obtained solid was washed with ethanol and acetone to acquire pure products **4a–k**.

[2-([3-(hydroxy- κ O)-1-phenyl-1*H*-pyrazol-4-yl]methylidene)amino- κ N)benzoato(2-)- κ O](phenyl)boron (4a**)**. Yellow solid; yield 72% (282 mg); m.p. 324–325 °C. IR (ν_{max} , cm^{-1}): 3127 (CH_{arom}), 1696, 1627, 1582, 1404 (C=O, C=N, C=C), 1175, 1026 (C–O), 758, 686 (C=C benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 7.09–7.14 (m, 3H, 3'', 4'', 5''-H), 7.18–7.22 (m, 2H, 2'', 6''-H), 7.41 (t, $J = 7.31 \text{ Hz}$, m, 1H, 4'-H), 7.50–7.53 (m, 1H, 5'''-H), 7.54–7.57 (m, 2H, 3', 5'-H), 7.78–7.81 (m, 1H, 4'''-H), 7.92–7.95 (m, 2H, 2', 6'-H), 8.00 (dd, $J = 7.8, 1.5 \text{ Hz}$, 1H, 6'''-H), 8.12 (d, $J = 8.1 \text{ Hz}$, 1H, 3'''-H), 9.24 (s, 1H, 5-H), 9.65 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 104.8 (C-4), 119.5 (C-2', 6'), 119.9 (C-3'''), 123.4 (C-1'''), 127.9 (C-3'', 5''), 128.0 (C-4''), 128.3 (C-4'), 129.2 (C-5'''), 130.1 (C-3', 5'), 130.6 (C-2'', 6''), 131.0 (C-6'''), 132.7 (C-5), 135.1 (C-4'''), 138.8 (C-1'), 140.8 (C-2'''), 144.4 (C-1''), 156.6 (CHN), 162.0 (COO), 162.8 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm –117.9 (Pz N-2), –168.9 (Pz N-1), –194.3 (N⁺). ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 6.1 (B). HRMS (ESI⁺) for $\text{C}_{23}\text{H}_{16}\text{BN}_3\text{NaO}_3$ ($[\text{M} + \text{Na}]^+$) calcd 416.1181, found 416.1183.

[2-([3-(hydroxy- κ O)-1-phenyl-1*H*-pyrazol-4-yl]methylidene)amino- κ N)benzoato(2-)- κ O](4-methylphenyl)boron (4b**)**. Yellow solid; yield 63% (257 mg); m.p. 333–334 °C. IR (ν_{max} , cm^{-1}): 3126, 3069 (CH_{arom}), 1693, 1631, 1588, 1494, 1405 (C=O, C=N, C=C), 1164, 1021 (C–O), 754, 730, 683 (C=C of benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 2.04 (s, 3H, 4''-CH₃), 6.83 (d, $J = 7.8 \text{ Hz}$, 2H, 3'', 5''-H), 6.97 (d, $J = 7.8 \text{ Hz}$, 2H, 2'', 6''-H), 7.31–7.35 (m, 1H, 4'-H), 7.43–7.49 (m, 3H, 3', 5', 5'''-H), 7.69–7.74 (m, 1H, 4'''-H), 7.87–7.89 (m, 3H,

2',6',6'''-H), 8.15 (d, $J = 8.2$ Hz, 1H, 3'''-H), 9.35 (s, 1H, 5-H), 9.86 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 21.1 (4''-CH₃), 104.6 (C-4), 119.2 (C-2',6'), 119.8 (C-3'''), 123.0 (C-1'''), 128.1 (C-4'), 128.4 (C-3''',5'''), 129.0 (C-5'''), 130.0 (C-3',5'), 130.4 (C-2'',6''), 130.7 (C-6'''), 133.1 (C-5), 135.0 (C-4'''), 136.7 (C-4''), 138.6 (C-1'), 140.5 (C-2'''), 140.8 (C-1''), 156.6 (CHN), 161.9 (COO), 162.6 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm -117.8 (Pz N-2), -168.7 (Pz N-1), -193.8 (N⁺). ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 6.2 (B). HRMS (ESI⁺) for C₂₄H₁₈BN₃NaO₃ ([M + Na]⁺) calcd 430.1338, found 430.1338.

[2-([3-(hydroxy- κ O)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino- κ N)benzoato(2-)- κ O](4-methoxyphenyl)boron (4c). Yellow solid; yield 54% (220 mg); m.p. 323–324 °C. IR (ν_{max} , cm⁻¹): 3129 (CH_{arom.}), 1695, 1631, 1601, 1583, 1497 (C=O, C=N, C=C), 1163, 1020 (C-O), 753, 732, 682 (C=C of benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 3.52 (s, 3H, 4''-OCH₃) 6.57–7.62 (m, 2H, 3'',5''-H), 6.95–7.01 (m, 2H, 2'',6''-H), 7.30–7.35 (m, 1H, 4'-H), 7.44–7.48 (m, 3H, 3',5',5'''-H), 7.71–7.73 (m, 1H, 4'''-H), 7.87–7.89 (m, 3H, 2',6',6'''-H), 8.16 (d, $J = 8.2$ Hz, 1H, 3'''-H), 9.35 (s, 1H, 5-H), 9.86 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 55.1 (4''-OCH₃), 104.6 (C-4), 113.3 (C-3'', 5''), 119.2 (C-2',6'), 119.8 (C-3'''), 123.0 (C-1'''), 128.1 (C-4'), 129.0 (C-5'''), 130.0 (C-3', 5'), 130.7 (C-6'''), 131.7 (C-2'',6''), 133.0 (C-5), 135.0 (C-4'''), 135.6 (C-1''), 138.6 (C-1'), 140.5 (C-2'''), 156.5 (CHN), 159.01 (C-4''), 161.9 (COO), 162.6 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm -168.9 (Pz N-1), -193.8 (N⁺), Pz N-2 was not found. ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 6.3 (B). HRMS (ESI⁺) for C₂₄H₁₈BN₃NaO₄ ([M + Na]⁺) calcd 446.1287, found 446.1292.

(4-fluorophenyl)[2-([3-(hydroxy- κ O)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino- κ N)benzoato(2-)- κ O]boron (4d). Yellow solid; yield 47% (194 mg); m.p. 318–319 °C. IR (ν_{max} , cm⁻¹): 3129, 3073 (CH_{arom.}), 1696, 1629, 1582, 1405 (C=O, C=N, C=C), 1171, 1027 (C-O), 759, 731, 687 (C=C of benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 6.92–6.96 (m, 2H, 3'',5''-H), 7.20–7.24 (m, 2H, 2'',6''-H), 7.39–7.43 (m, 1H, 4'-H), 7.5–7.53 (m, 1H, 5'''-H), 7.54–7.56 (m, 2H, 3',5'-H), 7.78–7.81 (m, 1H, 4'''-H), 7.91–7.92 (m, 2H, 2',6'-H), 8.01 (dd, $J = 7.8, 1.5$ Hz, 1H, 6'''-H), 8.08 (d, $J = 8.2$ Hz, 1H, 3'''-H), 9.20 (s, 1H, 5-H), 9.56 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 104.2 (C-4), 114.3 (d, $J = 19.6$ Hz, C-3''',5'''), 119.1 (C-2',6'), 119.4 (C-3'''), 122.9 (C-1'''), 127.9 (C-4'), 128.7 (C-5'''), 129.7 (C-3',5'), 130.5 (C-6'''), 132.19 (C-5), 132.19 (d, $J = 14.4$ Hz, C-2'',6''), 134.7 (C-4'''), 138.4 (C-1'), 140.0 (C-1''), 140.2 (C-2'''), 156.3 (CHN), 161.4 (COO), 162.0 (d, $J = 243.2$ Hz, C-4''), 162.2 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm -117.3 (Pz N-2), -168.1 (Pz N-1), -194.3 (N⁺). ^{19}F NMR (376 MHz, DMSO- d_6): δ_{F} ppm -114.5 (F). ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 5.8 (B). HRMS (ESI⁺) for C₂₃H₁₅BFN₃NaO₃ ([M + Na]⁺) calcd 434.1087, found 434.1085.

[2-([3-(hydroxy- κ O)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino- κ N)benzoato(2-)- κ O][4-(trifluoromethyl)phenyl]boron (4e). Yellow solid; yield 58% (267 mg); m.p. 323–324 °C. IR (ν_{max} , cm⁻¹): 3131, 3075 (CH_{arom.}), 1696, 1627, 1583, 1499, 1407 (C=O, C=N, C=C), 1326, 1295, 1174, 1108 (C-O, C-F), 802, 756, 730, 683 (C=C of benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 7.31–7.34 (m, 3H, 4',2'',6''-H), 7.38–7.39 (m, 2H, 3'',5''-H), 7.44–7.49 (m, 3H, 3',5',5'''-H), 7.72–7.76 (m, 1H, 4'''-H), 7.86–7.90 (m, 2H, 2',6',6'''-H), 8.21 (d, $J = 8.2$ Hz, 1H, 3'''-H), 9.41 (s, 1H, 5-H), 9.91 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 104.5 (C-4), 119.3 (C-2',6'), 120.0 (C-3'''), 122.3 (C-1'''), 124.4 (q, $J = 3.9$ Hz, C-3'',5''), 124.6 (q, $J = 272.3$ Hz, 4''-CF₃), 128.1 (C-4'), 128.3 (q, $J = 31.4$ Hz, C-4''), 129.1 (C-5'''), 130.0 (C-3',5'), 130.7 (C-6'''), 131.1 (C-2'',6''), 133.3 (C-5), 135.2 (C-4'''), 138.5 (C-1'), 140.3 (C-2'''), 149.3 (C-1''), 157.4 (CHN), 161.6 (COO), 162.3 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm -117.6 (Pz N-2), -168.2 (Pz N-1), -196.9 (N⁺). ^{19}F NMR (376 MHz, DMSO- d_6): δ_{F} ppm -61.0 (CF₃). ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 5.6 (B). HRMS (ESI⁺) for C₂₄H₁₅BF₃N₃NaO₃ ([M + Na]⁺) calcd 484.1055, found 484.1059.

[2-([3-(hydroxy- κ O)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino- κ N)-5-methylbenzoato(2-)- κ O](phenyl)boron (4f). Yellow solid; yield 50% (204 mg); m.p. 342–343 °C. IR (ν_{max} , cm⁻¹): 3126, 3055 (CH_{arom.}), 1691, 1626, 1587, 1488, 1403 (C=O, C=N, C=C), 1175, 1021 (C-O), 864, 754, 732 (C=C of benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 2.33 (s, 3H, 5'''-CH₃), 7.05–7.10 (m, 3H, 3'',4'',5''-H), 7.14–7.16 (m, 2H, 2'',6''-H), 7.35–7.39 (m, 1H, 4'-H), 7.49–7.53 (m, 2H, 3',5'-H), 7.57 (dd, $J = 8.5, 2.1$ Hz, 1H, 4'''-H), 7.76 (d, $J = 2.0$ Hz,

1H, 6'''-H), 7.89–7.92 (m, 2H, 2',6'-H), 8.03 (d, $J = 8.8$ Hz, 1H, 3'''-H), 9.27 (s, 1H, 5-H), 9.71 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 20.6 (5'''-CH₃), 104.4 (C-4), 119.0 (C-2',6'), 119.3 (C-3'''), 122.6 (C-1'''), 127.5 (C-3'',4'',5''), 127.8 (C-4'), 129.7 (C-3',5'), 130.2 (C-2'',6''), 130.6 (C-6'''), 132.3 (C-5), 135.4 (C-4'''), 138.0 (C-2'''), 138.5 (C-1'), 138.8 (C-5'''), 144.0 (C-1''), 155.5 (CHN), 161.7 (COO), 162.3 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm –117.5 (Pz N-2), –169.0 (Pz N-1), –193.4 (N⁺). ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 5.8 (B). HRMS (ESI⁺) for C₂₄H₁₈BN₃NaO₃ ([M + Na]⁺) calcd 430.1338, found 430.1340.

[2-([3-(hydroxy-κO)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino-κN)-5-methylbenzoato(2-)-κO](4-methylphenyl)boron (4g). Yellow solid; yield 59% (249 mg); m.p. 339–340 °C. IR (ν_{max} , cm⁻¹): 3086, 3039 (CH_{arom.}), 1698, 1624, 1589, 1488, 1404 (C=O, C=N, C=C), 1218, 1167, 1038 (C–O), 785, 752, 732, 684 (C=C of benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 2.04 (s, 3H, 4''-CH₃), 2.28 (s, 3H, 5'''-CH₃), 6.83 (d, $J = 7.8$ Hz, 2H, 3'',5''-H), 6.93–6.98 (m, 2H, 2'',6''-H), 7.29–7.35 (m, 1H, 4'-H), 7.42–7.49 (m, 2H, 3',5'-H), 7.52 (dd, $J = 8.7, 2.1$ Hz, 1H, 4'''-H), 7.67 (d, $J = 2.0$ Hz, 1H, 6'''-H), 7.84–7.89 (m, 2H, 2',6'-H), 8.02 (d, $J = 8.4$ Hz, 1H, 3'''-H), 9.32 (s, 1H, 5-H), 9.81 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 20.8 (5'''-CH₃), 21.1 (4''-CH₃), 104.5 (C-4), 119.2 (C-2',6'), 119.6 (C-3'''), 122.7 (C-1'''), 128.0 (C-4'), 128.4 (C-3'',5''), 130.0 (C-3',5'), 130.4 (C-2'',6''), 130.7 (C-6'''), 132.8 (C-5), 135.6 (C-4'''), 136.7 (C-4''), 138.2 (C-2'''), 138.6 (C-1'), 138.9 (C-5'''), 140.9 (C-1''), 155.8 (CHN), 162.0 (COO), 162.5 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm –169.3 (Pz N-1), –193.2 (N⁺), Pz N-2 was not found. ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 6.3 (B). HRMS (ESI⁺) for C₂₅H₂₀BN₃NaO₃ ([M + Na]⁺) calcd 444.1494, found 444.1495.

[2-([3-(hydroxy-κO)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino-κN)-5-methylbenzoato(2-)-κO](4-methoxyphenyl)boron (4h). Yellow solid; yield 56% (245 mg); m.p. 330–331 °C. IR (ν_{max} , cm⁻¹): 3126, 3037 (CH_{arom.}), 1694, 1631, 1588, 1494, 1406 (C=O, C=N, C=C), 1165, 1021 (C–O), 863, 795, 754, 730, 684 (C=C of benzene). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 2.28 (s, 3H, 5'''-CH₃), 3.52 (s, 3H, 4''-OCH₃), 6.56–6.63 (m, 2H, 3'',5''-H), 6.95–7.01 (m, 2H, 2'',6''-H), 7.31–7.35 (m, 1H, 4'-H), 7.45–7.49 (m, 2H, 3',5'-H), 7.53 (dd, $J = 8.6, 2.0$ Hz, 1H, 4'''-H), 7.68 (d, $J = 2.0$ Hz, 1H, 6'''-H), 7.84–7.88 (m, 2H, 2',6'-H), 8.03 (d, $J = 8.4$ Hz, 1H, 3'''-H), 9.32 (s, 1H, 5-H), 9.81 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 20.8 (5'''-CH₃), 55.1 (4''-OCH₃), 104.5 (C-4), 113.3 (C-3'',5''), 119.2 (C-2',6'), 119.6 (C-3'''), 122.7 (C-1'''), 128.0 (C-4'), 130.0 (C-3',5'), 130.7 (C-6'''), 131.6 (C-2'',6''), 132.8 (C-5), 135.6 (C-4'''), 135.8 (C-1''), 138.2 (C-2'''), 138.6 (C-1'), 138.9 (C-5'''), 155.7 (CHN), 159.0 (C-4''), 162.0 (COO), 162.6 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm –169.3 (Pz N-1), –192.9 (N⁺), Pz N-2 was not found. ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 5.9 (B). HRMS (ESI⁺) for C₂₅H₂₀BN₃NaO₄ ([M + Na]⁺) calcd 460.1444, found 460.1447.

[5-chloro-2-([3-(hydroxy-κO)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino-κN)benzoato(2-)-κO](phenyl)boron (4i). Yellow solid; yield 71% (303 mg); m.p. 365–366 °C. IR (ν_{max} , cm⁻¹): 3082 (CH_{arom.}), 1700, 1623, 1589, 1497, 1472, 1400 (C=O, C=N, C=C), 1179, 1021 (C–O), 776, 752, 688, 643 (C=C of benzene, C–Cl). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 7.05–7.10 (m, 3H, 3'',4'',5''-H), 7.12–7.16 (m, 2H, 2'',6''-H), 7.35–7.39 (m, 1H, 4'-H), 7.48–7.53 (m, 2H, 3',5'-H), 7.83–7.87 (m, 2H, 4''',6'''-H), 7.89–7.93 (m, 2H, 2',6'-H), 8.25–8.28 (m, 1H, 3'''-H), 9.37 (s, 1H, 5-H), 9.82 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 104.5 (C-4), 119.2 (C-2',6'), 122.1 (C-3'''), 124.4 (C-1'''), 127.7 (C-3'',5''), 127.8 (C-4''), 128.0 (C-4'), 129.7 (C-6'''), 129.8 (C-3',5'), 130.3 (C-2'',6''), 132.99 (C-5), 133.01 (C-5'''), 134.6 (C-4'''), 138.4 (C-1'), 139.4 (C-2'''), 143.6 (C-1''), 157.1 (CHN), 160.6 (COO), 162.4 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm –117.4 (Pz N-2), –168.0 (Pz N-1), –197.5 (N⁺). ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 5.9 (B). HRMS (ESI⁺) for C₂₃H₁₅BClN₃NaO₃ ([M + Na]⁺) calcd 450.0791, found 450.0794.

[5-chloro-2-([3-(hydroxy-κO)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino-κN)benzoato(2-)-κO](4-methylphenyl)boron (4j). Yellow solid; yield 55% (243 mg); m.p. 364–365 °C. IR (ν_{max} , cm⁻¹): 3105, 3085 (CH_{arom.}), 1701, 1617, 1587, 1497, 1469, 1400 (C=O, C=N, C=C), 1206, 1172, 1035 (C–O), 856, 772, 748, 679 (C=C of benzene, C–Cl). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 2.05 (s, 3H, 4''-CH₃), 6.84 (d, $J = 7.8$ Hz, 2H, 3'',5''-H), 6.97 (d, $J = 7.9$ Hz, 2H, 2'',6''-H), 7.32–7.36 (m, 1H, 4'-H), 7.45–7.49 (m, 2H, 3',5'-H), 7.79 (d, 1H, $J = 2.5$ Hz,

6'''-H), 7.81 (dd, $J = 8.6, 2.6$ Hz, 1H, 4'''-H), 7.86–7.90 (m, 2H, 2',6'-H), 8.25 (d, $J = 8.7$ Hz, 1H, 3'''-H), 9.39 (s, 1H, 5-H), 9.85 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 21.1 (4''-CH₃), 104.6 (C-4), 119.3 (C-2',6'), 122.3 (C-3'''), 124.5 (C-1'''), 128.2 (C-4'), 128.4 (C-3'',5''), 129.7 (C-6'''), 130.0 (C-3',5'), 130.4 (C-2'',6''), 133.0 (C-5), 133.3 (C-5'''), 134.7 (C-4'''), 136.9 (C-4''), 138.5 (C-1'), 139.5 (C-2'''), 140.7 (C-1''), 157.2 (CHN), 160.8 (COO), 162.5 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm, −168.6 (Pz N-1), −197.9 (N⁺), Pz N-2 was not found. ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 6.5 (B). HRMS (ESI⁺) for C₂₄H₁₇BCIN₃NaO₄ ([M + Na]⁺) calcd 464.0948, found 464.0952.

[5-chloro-2-([3-(hydroxy-κO)-1-phenyl-1H-pyrazol-4-yl]methylidene)amino-κN)benzoato(2-)-κO](4-methoxyphenyl)boron (4k). Yellow solid; yield 48% (220 mg); m.p. 333–334 °C. IR (ν_{max} , cm^{−1}): 3128, 3040 (CH_{arom.}), 1694, 1633, 1591, 1477, 1405 (C=O, C=N, C=C), 1182, 1010 (C–O), 861, 754, 728, 669 (C=C of benzene, C–Cl). ^1H NMR (700 MHz, DMSO- d_6): δ_{H} ppm 3.55 (s, 3H, 4''-OCH₃), 6.58–6.66 (m, 2H, 3'',5''-H), 7.98–7.04 (m, 2H, 2'',6''-H), 7.34–7.36 (m, 1H, 4'-H), 7.46–7.53 (m, 2H, 3',5'-H), 7.81–7.86 (m, 2H, 4''',6'''-H), 7.88–7.92 (m, 2H, 2',6'-H), 8.23–8.27 (m, 1H, 3'''-H), 9.37 (s, 1H, 5-H), 9.83 (s, 1H, CHN). ^{13}C NMR (176 MHz, DMSO- d_6): δ_{C} ppm 55.0 (4''-OCH₃), 104.6 (C-4), 113.3 (C-3'',5''), 119.2 (C-2',6'), 122.2 (C-3'''), 124.5 (C-1'''), 128.1 (C-4'), 129.7 (C-6'''), 129.9 (C-3',5'), 131.7 (C-2'',6''), 133.0 (C-5), 133.1 (C-5'''), 134.7 (C-4'''), 135.2 (C-1''), 138.5 (C-1'), 139.5 (C-2'''), 156.9 (CHN), 159.1 (C-4''), 160.8 (COO), 162.5 (C-3). ^{15}N NMR (71 MHz, DMSO- d_6): δ_{N} ppm −117.8 (Pz N-2), −168.0 (Pz N-1), −196.8 (N⁺). ^{11}B NMR (128 MHz, DMSO- d_6): δ_{B} ppm 6.2 (B). HRMS (ESI⁺) for C₂₄H₁₇BCIN₃NaO₄ ([M + Na]⁺) calcd 480.0897, found 480.0898.

4. Conclusions

In conclusion, a series of novel pyrazole-containing boron (III) complexes were synthesized from 3-hydroxy-1-phenyl-1H-pyrazole-4-carbaldehyde, 2-aminobenzene-carboxylic acids, and boronic acids via a one-pot multicomponent reaction, achieving good yields. The novel compounds were characterized via IR and advanced NMR spectroscopies as well as HRMS data. Additionally, X-ray single crystal analysis showed the presence of an asymmetric boron center and two enantiomers in each unit cell of crystals. The photophysical properties of the obtained compounds were investigated in different solvents. The compounds were faintly luminescent in THF, MeOH, ACN, and DMF solutions, and demonstrated aggregation-induced emission enhancement in mixed THF–water solutions. These compounds can be further investigated as luminescent materials or probes.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules29143432/s1>, Figures S1–S10: Fluorescence emission spectra of compounds 4b–4k in mixed THF–water solutions. Figures S11–S56: ^1H , ^{13}C , ^{19}F ^{11}B NMR and HRMS (ESI) spectra of compounds 4a–k.

Author Contributions: Conceptualization, A.Š.; methodology, A.Š. and E.A.; formal analysis, A.Š. and E.A.; investigation, V.S., S.B. and A.B.; resources, A.Š. and E.A.; data curation, A.Š., V.S., A.B. and E.A.; writing—original draft preparation, A.Š., E.A., V.S. and A.B.; writing—review and editing, A.Š. and E.A.; visualization, A.Š. and A.B.; supervision, E.A. and A.Š.; funding acquisition, A.Š. and E.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Research Council of Lithuania (No. S-MIP-23-51).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article and Supplementary Materials.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Heravi, M.M.; Zadsirjana, V. Prescribed drugs containing nitrogen heterocycles: An overview. *RSC Adv.* **2020**, *10*, 44247–44311. [[CrossRef](#)] [[PubMed](#)]
2. Wu, Y.-J. Heterocycles and Medicine: A Survey of the Heterocyclic Drugs Approved by the U.S. FDA from 2000 to Present. In *Progress in Heterocyclic Chemistry*, 1st ed.; Gribble, G.W., Joule, A.J., Eds.; Elsevier: Amsterdam, The Netherlands, 2012; Volume 24, pp. 1–53.
3. Lamberth, C. Heterocyclic chemistry in crop protection. *Pest Manag. Sci.* **2013**, *69*, 1106–1114. [[CrossRef](#)]
4. Jeschke, P. Recent developments in fluorine-containing pesticides. *Pest Manag. Sci.* **2024**, *80*, 3065–3087. [[CrossRef](#)] [[PubMed](#)]
5. Iftikhar, R.; Khan, F.Z.; Naeem, N. Recent synthetic strategies of small heterocyclic organic molecules with optoelectronic applications: A review. *Mol. Divers.* **2024**, *28*, 271–307. [[CrossRef](#)] [[PubMed](#)]
6. Torres-Méndez, C.; Axelsson, M.; Tian, H. Small Organic Molecular Electrocatalysts for Fuels Production. *Angew. Chem. Int. Ed.* **2024**, *63*, e202312879. [[CrossRef](#)] [[PubMed](#)]
7. Bastos, I.M.; Rebelo, S.; Silva, V.L.M. A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy. *Biochem. Pharmacol.* **2024**, *221*, 116045. [[CrossRef](#)]
8. Xu, Z.; Zhuang, Y.; Chen, Q. Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers. *Eur. J. Med. Chem.* **2023**, *257*, 115495. [[CrossRef](#)]
9. Basha, N.J. Small Molecules as Anti-inflammatory Agents: Molecular Mechanisms and Heterocycles as Inhibitors of Signaling Pathways. *ChemistrySelect* **2023**, *8*, e202204723. [[CrossRef](#)]
10. Toulis, K.A.; Nirantharakumar, K.; Pourzitaki, C.; Barnett, A.H.; Tahrani, A.A. Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. *Drugs* **2020**, *80*, 467–475. [[CrossRef](#)]
11. McCormack, P.L. Celecoxib. *Drugs* **2011**, *71*, 2457–2489. [[CrossRef](#)] [[PubMed](#)]
12. Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.; O'Brien, J.A.; Lemaire, W.; Williams, D.L.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; et al. Discovery of Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 5 from a Series of *N*-(1,3-Diphenyl-1*H*-pyrazol-5-yl)benzamides That Potentiate Receptor Function In Vivo. *J. Med. Chem.* **2004**, *47*, 5825–5828. [[CrossRef](#)] [[PubMed](#)]
13. Barth, F.; Rinaldi-Carmona, M. The Development of Cannabinoid Antagonists. *Curr. Med. Chem.* **1999**, *6*, 745–755. [[CrossRef](#)] [[PubMed](#)]
14. Secci, D.; Bolasco, A.; Chimenti, P.; Carradori, S. The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents. *Curr. Med. Chem.* **2011**, *18*, 5114–5144. [[CrossRef](#)] [[PubMed](#)]
15. Huang, D.; Liu, F.; Wen, S.; Wang, Y.; Fang, W.; Zhang, Z.; Ke, S. Substituted pyrazole derivatives as potential fungicidal agents. *Phytochem. Lett.* **2024**, *59*, 117–123. [[CrossRef](#)]
16. Khallaf, A.; Wang, P.; Zhuo, S.P.; Zhu, H.J.; Liu, H. Synthesis, insecticidal activities, and structure-activity relationships of 1,3,4-oxadiazole-ring-containing pyridylpyrazole-4-carboxamides as novel insecticides of the anthranilic diamide family. *J. Heterocycl. Chem.* **2021**, *58*, 2189–2202. [[CrossRef](#)]
17. Mykhailiuk, P.K. Fluorinated Pyrazoles: From Synthesis to Applications. *Chem. Rev.* **2021**, *121*, 1670–1715. [[CrossRef](#)] [[PubMed](#)]
18. Tigrerosa, A.; Portilla, J. Recent progress in chemosensors based on pyrazole derivatives. *RSC Adv.* **2020**, *10*, 19693–19712. [[CrossRef](#)] [[PubMed](#)]
19. Tigreros, A.; Portilla, J. Fluorescent Pyrazole Derivatives: An Attractive Scaffold for Biological Imaging Applications. *Curr. Chin. Sci.* **2021**, *1*, 197–206. [[CrossRef](#)]
20. Parshad, M.; Kumar, D.; Verma, V. A mini review on applications of pyrazole ligands in coordination compounds and metal organic frameworks. *Inorganica Chim. Acta* **2024**, *560*, 121789. [[CrossRef](#)]
21. Ebenezer, O.; Shapi, M.; Tuszynski, J.A. A Review of the Recent Development in the Synthesis and Biological Evaluations of Pyrazole Derivatives. *Biomedicines* **2022**, *10*, 1124. [[CrossRef](#)] [[PubMed](#)]
22. Jain, S. Epigrammatic Review on Heterocyclic Moiety Pyrazole: Applications and Synthesis Routes. *Mini-Rev. Org. Chem.* **2024**, *21*, 684–702. [[CrossRef](#)]
23. Kang, E.; Kim, H.T.; Joo, J.M. Transition-metal-catalyzed C–H functionalization of pyrazoles. *Org. Biomol. Chem.* **2020**, *18*, 6192–6210. [[CrossRef](#)] [[PubMed](#)]
24. Liu, L.; Durai, M.; Doucet, H. Transition Metal-Catalyzed Regiodivergent C–H Arylations of Aryl-Substituted Azoles. *Eur. J. Org. Chem.* **2022**, *2022*, e202200007. [[CrossRef](#)]
25. Becerra, D.; Abonia, R.; Castillo, J.-C. Recent Applications of the Multicomponent Synthesis for Bioactive Pyrazole Derivatives. *Molecules* **2022**, *27*, 4723. [[CrossRef](#)] [[PubMed](#)]
26. Medjahed, N.; Kibou, Z.; Berrichi, A.; Choukchou-Braham, N. Advances in Pyrazoles Rings' Syntheses by Heterogeneous Catalysts, Ionic Liquids, and Multicomponent Reactions—A Review. *Curr. Org. Chem.* **2023**, *27*, 471–509. [[CrossRef](#)]
27. Banfi, L.; Lambruschini, C. 100 years of isocyanide-based multicomponent reactions. *Mol. Divers.* **2024**, *28*, 1–2. [[CrossRef](#)] [[PubMed](#)]
28. Damera, T.; Pagadala, R.; Rana, S.; Jonnalagadda, S.B. A Concise Review of Multicomponent Reactions Using Novel Heterogeneous Catalysts under Microwave Irradiation. *Catalysts* **2023**, *13*, 1034. [[CrossRef](#)]
29. Banerjee, R.; Ali, D.; Mondal, N.; Choudhury, L.H. HFIP-Mediated Multicomponent Reactions: Synthesis of Pyrazole-Linked Thiazole Derivatives. *J. Org. Chem.* **2024**, *89*, 4423–4437. [[CrossRef](#)] [[PubMed](#)]

30. Méndez, Y.; Vasco, A.V.; Ivey, G.; Dias, A.L.; Gierth, P.; Sousa, B.B.; Navo, C.D.; Torres-Mozas, A.; Rodrigues, T.; Jiménez-Osés, G.; et al. Merging the Isonitrile-Tetrazine (4 + 1) Cycloaddition and the Ugi Four-Component Reaction into a Single Multicomponent Process. *Angew. Chem. Int. Ed.* **2023**, *62*, e202311186. [[CrossRef](#)] [[PubMed](#)]
31. Pearce, A.J.; Harkins, R.P.; Reiner, B.R.; Wotal, A.C.; Dunscomb, R.J.; Tonks, I.A. Multicomponent Pyrazole Synthesis from Alkynes, Nitriles, and Titanium Imido Complexes via Oxidatively Induced N–N Bond Coupling. *J. Am. Chem. Soc.* **2020**, *142*, 4390–4399. [[CrossRef](#)]
32. Savickienė, V.; Bieliauskas, A.; Belyakov, S.; Šačkus, A.; Arbačiauskienė, E. Synthesis and characterization of novel biheterocyclic compounds from 3-alkoxy-1H-pyrazole-4-carbaldehydes via multicomponent reactions. *J. Heterocycl. Chem.* **2024**, *61*, 927–947. [[CrossRef](#)]
33. Mahanta, C.S.; Ravichandiran, V.; Swain, S.P. Recent Developments in the Design of New Water-Soluble Boron Dipyrromethenes and Their Applications: An Updated Review. *ACS Appl. Bio Mater.* **2023**, *6*, 2995–3018. [[CrossRef](#)] [[PubMed](#)]
34. Kaur, M.; Janaagal, A.; Balsukuri, N.; Gupta, I. Evolution of Aza-BODIPY dyes—A hot topic. *Coord. Chem. Rev.* **2024**, *498*, 215428. [[CrossRef](#)]
35. Yuan, L.; Su, Y.; Cong, H.; Yu, B.; Shen, Y. Application of multifunctional small molecule fluorescent probe BODIPY in life science. *Dye. Pigment.* **2022**, *208*, 110851. [[CrossRef](#)]
36. İlhan, H.; Cakmak, Y. Functionalization of BODIPY Dyes with Additional C–N Double Bonds and Their Applications. *Top. Curr. Chem.* **2023**, *381*, 28. [[CrossRef](#)] [[PubMed](#)]
37. Wang, S.; Gai, L.; Chen, Y.; Ji, X.; Lu, H.; Guo, Z. Mitochondria-targeted BODIPY dyes for small molecule recognition, bio-imaging and photodynamic therapy. *Chem. Soc. Rev.* **2024**, *53*, 3976–4019. [[CrossRef](#)] [[PubMed](#)]
38. Chen, Z.; Chen, Y.; Xu, Y.; Shi, X.; Han, Z.; Bai, Y.; Fang, H.; He, W.; Guo, Z. BODIPY-Based Multifunctional Nanoparticles for Dual Mode Imaging-Guided Tumor Photothermal and Photodynamic Therapy. *ACS Appl. Bio Mater.* **2023**, *6*, 3406–3413. [[CrossRef](#)]
39. Cao, N.; Jiang, Y.; Song, Z.-B.; Chen, D.; Wu, D.; Chen, Z.-L.; Yan, Y.-J. Synthesis and evaluation of novel meso-substituted phenyl dithieno[3,2-*b*]thiophene-fused BODIPY derivatives as efficient photosensitizers for photodynamic therapy. *Eur. J. Med. Chem.* **2024**, *264*, 116012. [[CrossRef](#)]
40. Wang, J.; Gong, Q.; Jiao, L.; Hao, E. Research advances in BODIPY-assembled supramolecular photosensitizers for photodynamic therapy. *Coord. Chem. Rev.* **2023**, *496*, 215367. [[CrossRef](#)]
41. Yadava, I.S.; Misra, R. Design, synthesis and functionalization of BODIPY dyes: Applications in dye-sensitized solar cells (DSSCs) and photodynamic therapy (PDT). *J. Mater. Chem. C Mater. Opt. Electron. Devices* **2023**, *11*, 8688–8723. [[CrossRef](#)]
42. Bumagina, N.A.; Antina, E.V. Review of advances in development of fluorescent BODIPY probes (chemosensors and chemodosimeters) for cation recognition. *Coord. Chem. Rev.* **2024**, *505*, 215688. [[CrossRef](#)]
43. Kursunlu, A.N.; Bastug, E.; Guler, E. Importance of BODIPY-based Chemosensors for Cations and Anions in Bio-imaging Applications. *Curr. Anal. Chem.* **2022**, *18*, 163–175. [[CrossRef](#)]
44. Alcaide, M.M.; Santos, F.M.F.; Pais, V.F.; Carvalho, J.I.; Collado, D.; Pérez-Inestrosa, E.; Arteaga, J.F.; Boscá, F.; Gois, P.M.P.; Pischel, U. Electronic and Functional Scope of Boronic Acid Derived Salicylidenehydrazones (BASHY) Complexes as Fluorescent Dyes. *J. Org. Chem.* **2017**, *82*, 7151–7158. [[CrossRef](#)] [[PubMed](#)]
45. Guieu, S.; Esteves, C.I.C.; Rocha, J.; Silva, A.M.S. Multicomponent Synthesis of Luminescent Iminoboronates. *Molecules* **2020**, *25*, 6039. [[CrossRef](#)] [[PubMed](#)]
46. Santos, F.M.F.; Rosa, J.N.; Candeias, N.R.; Carvalho, C.P.; Matos, A.I.; Ventura, A.E.; Florindo, H.F.; Silva, L.C.; Pischel, U.; Gois, P.M.P. A Three-Component Assembly Promoted by Boronic Acids Delivers a Modular Fluorophore Platform (BASHY Dyes). *Chem. Eur. J.* **2016**, *22*, 1631. [[CrossRef](#)]
47. García-López, M.C.; Herrera-España, A.D.; Estupiñan-Jiménez, J.R.; González-Villasana, V.; Cáceres-Castillo, D.; Bojórquez-Quintal, E.; Elizondo, P.; Jiménez-Barrera, R.M.; Chan-Navarro, R. New luminescent organoboron esters based on damnacanthal: One-pot multicomponent synthesis, optical behavior, cytotoxicity, and selectivity studies against MDA-MBA-231 breast cancer cells. *N. J. Chem.* **2022**, *46*, 20138–20145. [[CrossRef](#)]
48. Cáceres-Castillo, D.; Mirón-López, G.; García-López, M.C.; Chan-Navarro, R.; Quijano-Quiñones, R.F.; Briceño-Vargas, F.M.; Cauich-Kumul, R.; Morales-Rojas, H.; Herrera-España, A.D. Boronate derivatives of damnacanthal: Synthesis, characterization, optical properties and theoretical calculations. *J. Mol. Struct.* **2023**, *1271*, 134048. [[CrossRef](#)]
49. Adib, M.; Sheikhi, E.; Bijanzadeh, H.R.; Zhu, L.-G. Microwave-assisted reaction between 2-aminobenzoic acids, 2-hydroxybenzaldehydes, and arylboronic acids: A one-pot three-component synthesis of bridgehead bicyclo[4.4.0]boron heterocycles. *Tetrahedron* **2012**, *68*, 3377–3383. [[CrossRef](#)]
50. Montalbano, F.; Cal, P.M.S.D.; Carvalho, M.A.B.R.; Gonçalves, L.M.; Lucas, S.D.; Guedes, R.C.; Veiros, L.F.; Moreira, R.; Gois, P.M.P. Discovery of new heterocycles with activity against human neutrophil elastase based on a boron promoted one-pot assembly reaction. *Org. Biomol. Chem.* **2013**, *11*, 4465–4472. [[CrossRef](#)] [[PubMed](#)]
51. Cal, P.M.S.D.; Sieglitz, F.; Santos, F.M.F.; Carvalho, C.P.; Guerreiro, A.; Bertoldo, J.B.; Pischel, U.; Gois, P.M.P.; Bernardes, G.J.L. Site-selective installation of BASHY fluorescent dyes to Annexin V for targeted detection of apoptotic cells. *Chem. Commun.* **2017**, *53*, 368–371. [[CrossRef](#)]
52. Zagorskytė, I.; Bieliauskas, A.; Pukalskienė, M.; Rollin, P.; Arbačiauskienė, E.; Šačkus, A. Glycerol-1,2-carbonate: A mild reagent for the N-glycerylation of pyrazolecarboxylates. *J. Heterocycl. Chem.* **2024**, *61*, 305–323. [[CrossRef](#)]

53. Urbonavičius, A.; Krikštolaitytė, S.; Bieliauskas, A.; Martynaitis, V.; Solovjova, J.; Žukauskaitė, A.; Arbačiauskienė, E.; Šačkus, A. Synthesis and Characterization of New Pyrano[2,3-*c*]pyrazole Derivatives as 3-Hydroxyflavone Analogues. *Molecules* **2023**, *28*, 6599. [[CrossRef](#)] [[PubMed](#)]
54. Dzedulionytė, K.; Fuxreiter, N.; Schreiber-Brynzak, E.; Žukauskaitė, A.; Šačkus, A.; Pichler, V.; Arbačiauskienė, E. Pyrazole-based lamellarin O analogues: Synthesis, biological evaluation and structure–activity relationships. *RSC Adv.* **2023**, *13*, 7897–7912. [[CrossRef](#)] [[PubMed](#)]
55. Varvuolytė, G.; Malina, L.; Bieliauskas, A.; Hošíková, B.; Simerská, H.; Kolářová, H.; Kleizienė, N.; Kryštof, V.; Šačkus, A.; Žukauskaitė, A. Synthesis and photodynamic properties of pyrazole-indole hybrids in the human skin melanoma cell line G361. *Dye. Pigment.* **2020**, *183*, 108666. [[CrossRef](#)]
56. Razmienė, B.; Vojáčková, V.; Řezníčková, E.; Malina, L.; Dambrauskienė, V.; Kubala, M.; Bajgar, R.; Kolářová, H.; Žukauskaitė, A.; Arbačiauskienė, E.; et al. Synthesis of *N*-aryl-2,6-diphenyl-2*H*-pyrazolo[4,3-*c*]pyridin-7-amines and their photodynamic properties in the human skin melanoma cell line G361. *Bioorganic Chem.* **2022**, *119*, 105570. [[CrossRef](#)] [[PubMed](#)]
57. Milišiūnaitė, V.; Kadlecová, A.; Žukauskaitė, A.; Doležal, K.; Strnad, M.; Voller, J.; Arbačiauskienė, E.; Holzer, W.; Šačkus, A. Synthesis and anthelmintic activity of benzopyrano[2,3-*c*]pyrazol-4(2*H*)-one derivatives. *Mol. Divers.* **2020**, *24*, 1025–1042. [[CrossRef](#)] [[PubMed](#)]
58. Arbačiauskienė, E.; Martynaitis, V.; Krikštolaitytė, S.; Holzer, W.; Šačkus, A. Synthesis of 3-substituted 1-phenyl-1*H*-pyrazole-4-carbaldehydes and the corresponding ethanones by Pd-catalysed cross-coupling reactions. *Arkivoc* **2011**, *11*, 1–21. [[CrossRef](#)]
59. Suman, G.R.; Pandey, M.; Chakravarthy, A.S.J. Review on new horizons of aggregation induced emission: From design to development. *Mater. Chem. Front.* **2021**, *5*, 1541–1584.
60. Braun, S.; Kalinowski, H.-O.; Berger, S. *150 and More Basic NMR Experiments: A Practical Course*, 2nd ed.; ACS: New York, NY, USA, 2000.
61. Buevich, A.V.; Williamson, R.T.; Martin, G.E. NMR Structure Elucidation of Small Organic Molecules and Natural Products: Choosing ADEQUATE vs HMBC. *J. Nat. Prod.* **2014**, *77*, 1942–1947. [[CrossRef](#)] [[PubMed](#)]
62. Sheldrick, G.M. A short history of SHELX. *Acta Cryst.* **2008**, *A64*, 112–122. [[CrossRef](#)] [[PubMed](#)]
63. Sheldrick, G.M. Crystal structure refinement with SHELXL. *Acta Cryst.* **2015**, *C71*, 3–8.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.